Placebo - Controlled Trial of Lisinopril in Pharmaceutical Optimized Lisinopril Omg [F-5] in Patients with Essential Hypertension for Efficacy and Biochemical Evaluation

ABSTRACT

Objective: The objective of this double-blind, randomized placebo-controlled trial study evaluating efficacy and biochemical effects of optimized lisinopril lOmg [F-5] as compared to placebo in adult patients with essential hypertension. Study Design. Double-blind, randomized placebo-controlled trial Place and Duration of Study This study was conducted at the Department of Biochemistry, University of Karachi from October 20 11 to January 2012. Materials and Methods: Patients were randomized to receive once optimized lisinopril lOmg [F-5] daily and Placebo once daily for 8 weeks and at the end of study efficacy and biochemical evaluation was done. Result: The patients treated with optimized lisinopril lOmg [F-5] alone, blood pressure reduction was lower, although significant; reaching values of 140.1 * 11.41 87.7 * 5.4 mmHg [p < 0.05 versus Placebo] by the end of eight weeks of treatment.. No significant variation of blood glucose was observed and different parameters of lipid profile were also observed during the eight weeks of treatment with antihypertensive regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and plasma lipid metabolism profile because drug used at low doses. Conclusion: We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Lisinopril lOmg [F-5] it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks